Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 4/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 6/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100370 | 0.89 | PRKCI (0.52) | PRKCIAURKBAURKANUDT1IGF1R | |
| Trifluoroacetic Acid SCHEMBL4092152 | 0.82 | KMT2A (0.47) | PRKCIAURKBAURKAJAK2JAK3 | |
| Trifluoroacetic Acid SCHEMBL4082520 | 0.82 | NPC1 (0.38) | PRKCIAURKBAURKAPBK | |
| Trifluoroacetic Acid SCHEMBL4082067 | 0.78 | PRKCI (0.54) | PRKCIAURKBAURKANUDT1IGF1R | |
| Trifluoroacetic Acid SCHEMBL4099482 | 0.77 | PRKCI (0.41) | PRKCIAURKBAURKANUDT1PBK | |
| Trifluoroacetic Acid SCHEMBL4082523 | 0.76 | PRKCI (0.44) | PRKCIAURKBAURKAGRM4MET | |
| Trifluoroacetic Acid SCHEMBL4088375 | 0.76 | CCNK (0.41) | PRKCIAURKBAURKANUDT1IGF1R | |
| Trifluoroacetic Acid SCHEMBL4097306 | 0.75 | PRKCI (0.50) | PRKCIAURKBAURKANUDT1IGF1R | |
| Trifluoroacetic Acid SCHEMBL4095832 | 0.74 | PRKCI (0.51) | PRKCIAURKBAURKANUDT1IGF1R | |
| Trifluoroacetic Acid SCHEMBL4092178 | 0.72 | MAPK14 (0.41) | PRKCIAURKBAURKAIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PRKCI 304/4885AURKB 198/4885AURKA 485/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PRKCI 304/4885AURKB 198/4885AURKA 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.